---
canonical_name: Topical NMN
alternate_names: Topical Nicotinamide Mononucleotide, Topical β-NMN, β-Nicotinamide Mononucleotide, NMN
canonical_topic: Topical NMN for Hair Regrowth
short_topic_lc: topical_nmn_hair
creation_date: 2026-0627-0330
creator_ai_fullname: Opus 4.8
---
# Topical NMN for Hair Regrowth
Evidence Review created on 06/27/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8
**Also known as:** Topical Nicotinamide Mononucleotide, Topical β-NMN, β-Nicotinamide Mononucleotide, NMN
## Motivation
Nicotinamide mononucleotide (NMN) is a small molecule the body uses to make NAD+, a helper compound that every cell needs to turn nutrients into usable energy and to repair itself. Levels of this helper compound fall with age, and the cells at the base of each hair follicle are among the most energy-hungry in the body. This has prompted interest in applying NMN directly to the scalp as a cream or serum, on the theory that restoring local energy supply could keep follicles in their active growing phase longer.
Interest in NMN exploded first as an oral longevity supplement, and the leap to hair is recent. A single laboratory study in mice and cultured human follicle cells reported that NMN restored hair growth in a model of hormone-driven thinning roughly as well as the standard topical drug it was compared against. That headline finding, widely repeated by supplement marketers, is the main reason topical NMN is now discussed for hair.
This review examines what is actually known about applying NMN to the scalp for hair regrowth: the proposed biology, the early laboratory and human evidence, the safety and sourcing questions, and where the gaps in knowledge remain.
**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
## Recommended Reading
This section lists high-level overviews and expert commentary that discuss NMN and its relationship to hair and follicle biology.
* [Does NMN Help With Hair Loss?](https://novoslabs.com/does-nmn-help-hair-loss/) - NOVOS
A longevity-science overview that walks through the NAD+–follicle energy hypothesis and the 2024 mouse and cell study in plain language, while flagging the absence of human topical data.
* [NMN's Role in Hair Follicle Regeneration](https://foryouth.co/blogs/magazine/nmns-role-in-hair-follicle-regeneration) - Souliac
A longevity-focused narrative explainer on how NMN and NAD+ are theorized to affect the hair cycle and follicle energy, useful for understanding the mechanistic framing behind topical NMN products.
* [NMN For Hair Growth and Hair Loss: A Look at Studies](https://neuroganhealth.com/blogs/news/nmn-for-hair-growth) - Cicak
A readable summary of the preclinical evidence, including how the topical and oral routes for NMN compare, that explicitly distinguishes mechanism from proven human benefit.
* [NMN could benefit hair growth, says Mitsubishi Corporation Life Sciences study](https://www.nutraingredients.com/Article/2025/10/06/nmn-could-benefit-hair-growth-says-mitsubishi-corporation-life-sciences-study/) - Koe
An industry-news report on the first human (oral) NMN hair trial, helpful as a critical counterpoint because it notes the study's small size and its paradoxical drop in total hair count.
* [The Science Behind NMN — A Stable, Reliable NAD+ Activator and Anti-Aging Molecule](https://pubmed.ncbi.nlm.nih.gov/32549859/) - Shade, 2020
A narrative overview of NMN's biochemistry, stability, and routes of delivery that provides the foundational context for why NMN is a candidate topical ingredient at all.
No content from the five priority experts could be found that addresses NMN specifically for hair regrowth, so general high-quality overviews and the foundational biochemistry review were used instead.
## Grokipedia
* [Nicotinamide mononucleotide](https://grokipedia.com/page/Nicotinamide_mononucleotide) - Grokipedia
Grokipedia's NMN article covers the molecule's biochemistry, its role as the immediate precursor to NAD+ in the salvage pathway, dietary sources, and the unsettled state of human efficacy evidence — useful background, though it does not address topical use for hair.
## Examine
* [Nicotinamide Mononucleotide](https://examine.com/supplements/nicotinamide-mononucleotide/) - Examine
Examine's evidence-graded monograph summarizes the human data on oral NMN (primarily aging, physical performance, and metabolic outcomes) and notes its shifting U.S. regulatory status; it does not cover topical application or hair regrowth.
## ConsumerLab
* [NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, NMN)](https://www.consumerlab.com/reviews/nmn-nadh-nicotinamide-riboside/nmn-nadh-nicotinamide-riboside/) - ConsumerLab
ConsumerLab's review tests the identity, label accuracy, and contamination of oral NMN and other NAD-booster products — relevant for raw-ingredient quality, though it does not evaluate topical NMN scalp formulations.
## Systematic Reviews
No systematic reviews or meta-analyses for Topical NMN were found on PubMed as of June 27, 2026.
## Mechanism of Action
The proposed rationale for topical NMN rests on NAD+ biology in the hair follicle. NMN is the immediate precursor to NAD+ (nicotinamide adenine dinucleotide, a coenzyme essential for energy production and DNA repair) via the salvage pathway. The matrix and dermal papilla cells at the base of an active follicle have extremely high energy demands, and NAD+ availability declines with age, so the hypothesis is that delivering NMN locally raises NAD+ and sustains the energy supply needed to keep follicles in their growth (anagen) phase.
The most detailed mechanistic data come from cultured human dermal papilla cells (HDPCs) — the signaling hub cells at the follicle base — exposed to dihydrotestosterone (DHT, the potent androgen that drives male- and female-pattern hair loss). In that work, DHT lowered cell viability and raised inflammatory signals interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α, all immune-signaling proteins that promote inflammation). NMN reduced these signals, an effect attributed to inhibition of the NF-κB p65 pathway (a master switch that turns on inflammatory genes). NMN also suppressed the androgen receptor (AR, the protein DHT acts through) and dickkopf-1 (DKK-1, a protein DHT uses to push follicles into dormancy), while increasing β-catenin and VEGF (vascular endothelial growth factor, which promotes the local blood supply). β-catenin is the central messenger of the Wnt pathway (a signaling cascade that tells follicles to grow), so raising it favors hair growth.
A competing consideration weighs against the topical route specifically: a skin-permeation study using an artificial membrane model found that NMN reached only the upper (papillary) dermis and did not penetrate deeper, where the hair bulb of a terminal follicle sits. This raises the question of whether enough NMN can physically reach the follicle base when applied to intact scalp skin.
NMN is a small, water-soluble, acidic molecule (formula C₁₁H₁₅N₂O₈P, ~334 Da) rather than a classic drug, so it has no defined systemic half-life, receptor selectivity, or cytochrome P450 (liver enzyme) metabolism in the pharmacological sense; once converted, it feeds the ubiquitous NAD+ pool. Its chemical stability in cosmetic carriers is favorable, with a reported half-life of roughly 7 months at 20°C in a yeast-fermented filtrate.
## Historical Context & Evolution
NMN was not originally developed for hair. It entered prominence through aging research in the 2010s, when studies in mice showed that boosting NAD+ with NMN improved mitochondrial function, metabolism, and various age-related decline measures. This launched NMN as one of the most heavily marketed oral longevity supplements worldwide.
The pivot to hair is very recent and rests on a narrow base. The original observation that NMN could promote hair growth comes from a 2024 laboratory study in which NMN was applied topically to the skin of mice with hormone-induced thinning, with cell-based experiments added to probe the mechanism. The cosmetic industry quickly extended NMN's "skin anti-aging" positioning — supported by data showing NMN can boost collagen production in skin fibroblasts — into scalp and hair products.
Because the field is so young, there is no long arc of scientific opinion to trace, and no established consensus has formed for or against topical NMN for hair. The current standing is best described as an early mechanistic hypothesis with a single supportive preclinical study, a small oral human trial with mixed results, and an open question about whether topically applied NMN can reach the follicle. New evidence on either side could readily shift the picture.
## Expected Benefits
A dedicated search of PubMed, clinical and expert sources, and product literature was performed to assemble the complete benefit profile. The defining feature of this topic is that essentially all direct hair benefits rest on a single preclinical study; human hair data exist only for the oral route.
### High 🟩 🟩 🟩
(No benefits qualify for a High evidence grade. There are no randomized controlled trials of topical NMN for hair regrowth in humans.)
### Medium 🟩 🟩
(No benefits qualify for a Medium evidence grade.)
### Low 🟩
#### Reduced DHT-Driven Follicle Atrophy in Preclinical Models
In a mouse model of dihydrotestosterone-induced thinning, NMN reversed follicle atrophy, hair thinning, and sparsity, with effects described as comparable to minoxidil; in parallel, cultured human dermal papilla cells exposed to DHT showed lower inflammatory signaling and restored growth-promoting markers (β-catenin, VEGF) with NMN. The evidence basis is one published mouse-plus-cell study, so the grade is Low and the finding has not been confirmed in humans.
**Magnitude:** Not quantified in available studies.
#### Local Anti-Inflammatory and Antioxidant Effect at the Follicle
NMN lowered DHT-induced release of IL-6, IL-1β, and TNF-α and protected dermal papilla cells from oxidative-stress damage by suppressing the NF-κB p65 pathway. Because chronic micro-inflammation around the follicle (perifollicular inflammation) is implicated in pattern hair loss, dampening it is a plausible contributor to benefit; the evidence is from cell culture only.
**Magnitude:** Not quantified in available studies.
### Speculative 🟨
#### Improved Dermal Support via Collagen Stimulation
Separate from follicle signaling, topically permeating NMN increased type I collagen production in human skin fibroblasts in an artificial-membrane study. Better dermal and perifollicular structural support could in theory create a healthier environment for hair, but this is an indirect, mechanistic inference with no hair-outcome data, so it is Speculative.
#### Carryover from Oral NMN Hair Findings
A small oral human trial reported increased anagen hair density and hair diameter, alongside a paradoxical drop in total hair count. Whether any such effect would translate to topical delivery is unknown and untested; the basis is anecdotal extrapolation from a different route of administration.
## Benefit-Modifying Factors
* **Androgen status (DHT exposure):** The single preclinical benefit was specifically in a DHT-driven model, suggesting topical NMN may matter most for hormone-driven (androgenetic) thinning rather than for normal hair, where neither NMN nor minoxidil improved regrowth in mice.
* **Genetic polymorphisms (AR, 5-alpha-reductase):** Variants in the androgen receptor gene (AR, the protein DHT acts through) and in the SRD5A enzymes (the 5-alpha-reductase enzymes that convert testosterone to DHT) set how strongly the follicle is driven by androgens; because NMN's only documented benefit was anti-androgenic in a DHT model, individuals whose genetics confer greater DHT sensitivity could in theory derive more benefit, though this is untested for NMN.
* **Baseline scalp NAD+ and age:** Because NAD+ declines with age, older individuals with lower baseline follicle NAD+ are the population in whom restoring it is theorized to help most; this remains an untested assumption for hair.
* **Sex-based differences:** No hair-specific data exist by sex for topical NMN. The oral human hair signal was generated only in women, and pattern hair loss differs by sex in its DHT dependence, so benefit could plausibly differ between men and women.
* **Skin barrier and follicle depth:** Because permeation data suggest NMN may not reach the deep terminal-hair bulb through intact skin, individuals or formulations with greater follicular delivery (e.g., compromised barrier, microneedling, penetration enhancers) might see different results.
* **Pre-existing scalp conditions:** Inflammatory scalp conditions could in principle either enhance any anti-inflammatory benefit or alter penetration; no data address this.
## Potential Risks & Side Effects
A dedicated search of drug-reference and safety literature was performed. There are no published safety studies of topical NMN applied to the scalp; the risk profile is therefore inferred from oral NMN safety data, from cosmetic NMN skin data, and from general topical-product principles.
### High 🟥 🟥 🟥
(No risks qualify for a High evidence grade specific to topical NMN.)
### Medium 🟥 🟥
(No risks qualify for a Medium evidence grade specific to topical NMN.)
### Low 🟥
#### Lack of Established Topical Safety Data
The principal risk is the near-total absence of human safety evaluation for NMN applied to the scalp. Oral NMN has been studied and found well tolerated, but topical pharmacokinetics, long-term scalp exposure, and follicular accumulation are uncharacterized. The evidence basis is the absence of dedicated studies rather than reported harm, so any adverse-event rate is simply unknown.
**Magnitude:** Not quantified in available studies.
#### Local Skin Irritation and Contact Reactions
As with most topical actives, application to the scalp can cause irritation, redness, itching, or contact dermatitis, driven either by NMN's acidic nature or, more often, by the carrier ingredients (solvents, preservatives, fragrances) in a serum or cream. This is a general expectation for topicals rather than an NMN-specific finding.
**Magnitude:** Not quantified in available studies.
### Speculative 🟨
#### Systemic Absorption and NAD+ Pathway Effects
If meaningful amounts of topically applied NMN were absorbed, theoretical concerns from the oral-NMN discussion — such as a laboratory signal that long-term high NMN exposure might stress the kidneys in older individuals, and debate about NAD+ pathway effects on cell proliferation — could become relevant. Permeation data suggest limited systemic delivery, so this is speculative and based on mechanistic reasoning, not topical reports.
#### Product Quality and Mislabeling Harms
Independent testing of the oral NMN market found many products contained little or no detectable NMN, and the same quality risk could apply to topical formulations, meaning an unverified product could expose the scalp to undeclared excipients or contaminants rather than NMN. This is an inference from supplement-market findings, not a documented topical adverse event.
## Risk-Modifying Factors
* **Skin sensitivity and atopy:** Individuals with sensitive skin, eczema, or known contact allergies are more likely to react to the actives or carriers in a topical NMN product and warrant patch testing first.
* **Compromised scalp barrier:** Broken, inflamed, or recently treated (e.g., microneedled) scalp skin could increase absorption and irritation, modifying both local and any systemic risk.
* **Renal function and age:** Older individuals or those with reduced kidney function would be the theoretical concern population if systemic absorption occurred, given the laboratory kidney signal raised for high-dose NMN exposure.
* **Sex-based differences:** No sex-specific topical safety data exist; any local irritation or contact-reaction risk is expected to track skin sensitivity rather than sex, and because the only human NMN hair exposure (oral) was studied in women, the topical irritation and any theoretical systemic profile in men is entirely uncharacterized.
* **Concurrent topical actives:** Using NMN alongside other potentially irritating scalp products (e.g., topical retinoids, high-strength minoxidil solutions with propylene glycol) could compound irritation.
* **Product source and verification:** Because mislabeling is documented in the NMN market, the risk profile depends heavily on whether a product is third-party tested for identity and contaminants.
## Key Interactions & Contraindications
* **Prescription drug interactions:** No documented interactions exist for topical NMN. Theoretically, co-applied topical hair drugs — minoxidil (a vasodilator hair-growth drug) or topical finasteride (a 5-alpha-reductase inhibitor that blocks DHT formation) — share the follicle as a target, but no interaction data exist; severity is unknown and the consequence would most likely be additive irritation rather than a pharmacological conflict.
* **Over-the-counter medication interactions:** None established. Combining with OTC topical products containing strong solvents or exfoliating acids could increase local irritation (caution; consequence: dermatitis); separating applications in time is a reasonable mitigation.
* **Supplement interactions:** None established for topical use. Other NAD+ precursors taken orally — nicotinamide riboside (NR) or niacin — feed the same NAD+ pool, so simultaneous heavy supplementation is theoretically additive at the pathway level (monitor; consequence: unknown), though topical delivery makes a meaningful systemic interaction unlikely.
* **Additive-effect supplements/topicals:** Topical agents that also stimulate the Wnt/β-catenin or VEGF pathways (e.g., minoxidil, certain peptide serums) could be additive with NMN's proposed mechanism, which may be desirable but increases the chance of cumulative scalp irritation.
* **Other intervention interactions:** Procedures such as microneedling or platelet-rich plasma that breach the skin barrier would alter NMN delivery and should be considered before combining (caution; consequence: increased absorption and irritation).
* **Populations who should avoid this intervention:** Because safety is uncharacterized, those who are pregnant or breastfeeding, children, and individuals with active scalp infection, open lesions, or known sensitivity to formulation ingredients should avoid topical NMN; those with significant kidney impairment should be cautious given the theoretical systemic concern.
## Risk Mitigation Strategies
* **Patch test before scalp use:** Apply a small amount to inner forearm skin for 24–48 hours and check for redness or itching before scalp application, to catch contact irritation or allergy before broad exposure.
* **Start with low frequency:** Begin with once-daily or alternate-day application rather than multiple daily applications, escalating only if well tolerated, to limit cumulative irritation from NMN or its carrier.
* **Choose third-party-tested products:** Select formulations with independent verification of NMN identity and contaminant screening (heavy metals, microbial), directly mitigating the documented risk of mislabeled or adulterated NMN products.
* **Avoid broken or inflamed skin:** Do not apply over cuts, active dermatitis, or freshly microneedled scalp, which mitigates excessive absorption and the theoretical systemic and irritation risks.
* **Separate from other strong topicals:** Space NMN application several hours apart from potentially irritating actives (high-strength minoxidil, acids, retinoids) to reduce the chance of additive scalp irritation.
* **Discontinue on reaction and consult:** Stop use and seek dermatologic advice if persistent redness, scaling, or shedding occurs, preventing a mild irritant reaction from progressing.
## Therapeutic Protocol
There is no validated clinical protocol for topical NMN for hair, because no human topical hair trials have been published. What follows synthesizes the preclinical study design and general topical-active practice; it is not an established regimen.
* **Standard approach (preclinical-derived):** In the foundational animal work, a 0.5% NMN preparation was applied topically to depilated skin daily, with hair regrowth assessed over roughly two weeks; consumer products mirror this with daily scalp application of an NMN serum or cream, typically described in the percent-by-weight range used for cosmetic actives. No optimal human concentration has been established.
* **Competing approaches:** The main alternatives are oral NMN (the only route with any human hair data, from a small trial) and established topical hair drugs (minoxidil; topical finasteride). NMN is best viewed as an unproven add-on to, not a replacement for, evidence-based options; no approach should be framed as the default given the thin data.
* **Practitioner/clinic origin:** The topical route traces to the 2024 laboratory group (Xu and colleagues) rather than a clinic; the oral hair signal traces to a Mitsubishi Corporation Life Sciences–affiliated research group — a manufacturer of NMN, a conflict of interest worth noting.
* **Best time of day:** No time-of-day data exist for topical NMN; cosmetic actives are commonly applied to a clean, dry scalp once or twice daily, and consistency matters more than timing.
* **Half-life of the compound:** NMN has no defined topical or systemic half-life as a drug; in a cosmetic carrier its chemical half-life was roughly 7 months at 20°C, indicating formulation stability rather than a dosing interval.
* **Single versus split application:** No comparative data exist; consumer regimens use either once-daily or twice-daily application without evidence favoring either.
* **Genetic polymorphisms:** No pharmacogenetic data exist for topical NMN. Variation in androgen receptor sensitivity and 5-alpha-reductase activity influences pattern hair loss generally and could plausibly affect who responds, but this is untested for NMN.
* **Sex-based differences:** No topical dosing differences are established; the only human hair signal (oral) was in women, leaving male response unquantified.
* **Age considerations:** Lower baseline NAD+ in older individuals is the theoretical rationale for use, but no age-specific topical dosing exists; older skin may also differ in penetration.
* **Baseline biomarkers:** No biomarker-guided dosing exists; baseline follicle NAD+ cannot be measured in practice.
* **Pre-existing conditions:** Active scalp disease should be treated before considering a cosmetic active, as inflammation alters both penetration and tolerability.
## Discontinuation & Cycling
* **Lifelong versus short-term:** As with all hair-loss interventions that target an ongoing process, any benefit would be expected to depend on continued use; there is no evidence topical NMN produces a lasting change after stopping, so it should be regarded as a maintenance approach if used at all.
* **Withdrawal effects:** No withdrawal syndrome is known or expected for topical NMN. Unlike minoxidil, where stopping can trigger a wave of shedding of drug-dependent hairs, no such rebound has been documented for NMN because no controlled discontinuation has been studied.
* **Tapering protocol:** No tapering is described or needed; topical NMN can be stopped abruptly, as there is no pharmacological dependence.
* **Cycling:** No evidence supports cycling on and off to maintain efficacy; cycling is neither recommended nor studied for this intervention.
* **Practical discontinuation:** Because effects (if any) are unproven and reversible, discontinuation is simply ceasing application; any gains would be expected to regress over subsequent hair cycles as with other hair actives.
## Sourcing and Quality
* **Identity verification is paramount:** Independent testing of the oral NMN market found many products contained little or no actual NMN, so confirming that a topical product truly contains stated NMN — ideally via a third-party certificate of analysis — is the single most important sourcing step.
* **Formulation and stability:** NMN is reasonably stable in appropriate cosmetic carriers (one study reported a ~7-month half-life in a yeast-fermented filtrate), so prefer products formulated for stability (opaque, sealed packaging) over generic mixtures; degraded NMN converts to nicotinamide.
* **Purity and contaminants:** Look for screening of heavy metals (lead, arsenic, cadmium) and microbial contamination, particularly important for a leave-on scalp product applied to potentially broken skin.
* **Source form (β-NMN):** The biologically relevant form is β-NMN; reputable suppliers specify the β isomer and its purity, which is worth confirming on the label or documentation.
* **Reputable channels:** Because U.S. regulatory status of NMN as a supplement is contested, sourcing may be inconsistent; favor established cosmetic brands or compounding pharmacies that provide testing documentation over unverified marketplace sellers.
## Practical Considerations
* **Time to effect:** Unknown for topical NMN in humans; by analogy to the hair cycle and to other hair actives, any visible change would not be expected before roughly 3–6 months of consistent use, and the preclinical mouse signal emerged over about 6 weeks.
* **Common pitfalls:** Treating topical NMN as a proven minoxidil substitute (the comparison comes from mice, not humans), expecting fast results, abandoning evidence-based treatments in favor of it, and buying unverified products that may not contain NMN.
* **Regulatory status:** NMN's status is unsettled — the U.S. FDA has taken the position that NMN cannot be sold as a dietary supplement, and topical/cosmetic use occupies a separate, lightly regulated category; topical NMN for hair is entirely off-label and unapproved as a drug.
* **Cost and accessibility:** Topical NMN products are generally a premium-priced cosmetic category, and availability fluctuates with the regulatory situation, which can make consistent long-term sourcing both costly and uncertain.
* **Realistic expectations:** Given the single preclinical study and absence of human topical hair trials, it should be approached as experimental, not as an established treatment.
## Interaction with Foundational Habits
* **Sleep:** Indirect, no documented interaction. Topical NMN is not expected to affect sleep, since meaningful systemic absorption appears limited; conversely, adequate sleep supports the cellular repair and energy processes NMN is theorized to assist, so good sleep is complementary rather than interacting.
* **Nutrition:** Indirect, potentiating in theory. NAD+ status is shaped by overall niacin-equivalent (vitamin B3 family) intake and metabolic health, so a diet supporting NAD+ could in principle align with topical NMN's mechanism; no specific foods to include or avoid are established for the topical route.
* **Exercise:** Indirect, none documented for the topical route. Exercise raises NAD+ systemically and supports follicle blood supply, which is mechanistically consonant with NMN's proposed action, but there is no evidence exercise alters topical NMN's local effect or vice versa, and no timing considerations apply.
* **Stress management:** Indirect, potentiating in theory. Chronic stress can worsen hair shedding (e.g., telogen effluvium) and drive inflammation, the same NF-κB-linked process NMN is proposed to dampen at the follicle, so stress reduction may complement any anti-inflammatory benefit; no direct interaction or cortisol effect is documented.
## Monitoring Protocol & Defining Success
Before starting, a baseline assessment of the scalp and hair allows any change to be judged objectively, since topical NMN has no relevant blood biomarker. Standardized baseline photographs of the affected area under consistent lighting are the most practical reference point.
Ongoing monitoring is best done on the hair cycle's timescale: reassess with matched photographs at baseline, then at roughly 3 months and 6 months, and every 6 months thereafter, since changes in hair density and caliber take months to manifest. Routine blood testing is not indicated for a topical with limited systemic absorption; the table below lists only tests relevant if systemic exposure or underlying hair-loss drivers are a concern.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|----------------|
| Ferritin (iron stores) | 50–70 ng/mL (functional target for hair) | Low iron stores are a common, correctable cause of hair shedding that can mask or mimic poor response | Conventional "normal" starts ~15–30 ng/mL, well below the hair-relevant target; fast not required |
| Vitamin D, 25-OH | 40–60 ng/mL (functional) | Low vitamin D is associated with hair-cycle disruption and is worth excluding as a confounder | Conventional cutoff for "sufficiency" is ~30 ng/mL; not time-of-day sensitive |
| TSH | 1.0–2.0 mIU/L (functional) | Thyroid dysfunction is a frequent driver of diffuse hair loss that should be ruled out | TSH (thyroid-stimulating hormone); conventional range extends to ~4.0–4.5 mIU/L; best paired with free T4; morning draw preferred |
| eGFR | >90 mL/min/1.73 m² | Only if systemic NMN exposure is a concern, given the theoretical high-dose kidney signal | eGFR (estimated glomerular filtration rate, a measure of kidney filtration); reasonable baseline for older users; derived from serum creatinine; not routinely needed for topical use |
Qualitative markers are often the most accessible signs of change:
* Reduced daily shedding (e.g., fewer hairs in the brush or drain)
* Visible increase in density or coverage at the hairline or part
* Improved hair caliber or texture (hairs feeling thicker, less wispy)
* Scalp tolerability — absence of redness, itching, or flaking from the product
## Emerging Research
* **No registered topical NMN hair trials:** A search of ClinicalTrials.gov returned no interventional studies of topical (or oral) NMN for hair loss or hair growth as of mid-2026, underscoring how early this field is; the registered NMN trials concern aging, metabolism, and other systemic endpoints.
* **Foundational preclinical study:** The single mouse-and-cell study by [Xu et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38398550/) is the cornerstone of the topical hypothesis and the obvious starting point for any future controlled human work; it reported NMN reversing DHT-induced thinning with minoxidil-comparable effect in mice.
* **Skin-permeation evidence (could weaken the case):** The artificial-membrane study by [Betsuno et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40317586/) found NMN reached only the papillary dermis and not deeper tissue, raising a delivery question that future formulation research (penetration enhancers, microneedle-assisted delivery) will need to resolve.
* **Oral human hair signal (could strengthen or complicate the case):** The first human NMN hair trial (oral, in middle-aged women, published in *Cosmetics*, [doi:10.3390/cosmetics12050204](https://doi.org/10.3390/cosmetics12050204)) reported increased anagen density and hair diameter but a paradoxical fall in total hair count — a mixed result that highlights the need for controlled topical studies and was conducted by a manufacturer-affiliated group.
* **NAD+ delivery science:** Broader work on how NAD+ precursors are absorbed and metabolized, summarized in narrative overviews such as [Shade, 2020](https://pubmed.ncbi.nlm.nih.gov/32549859/), will shape whether topical NMN can be formulated to reach the follicle at active concentrations.
## Conclusion
Topical NMN for hair regrowth is an early-stage, largely unproven idea built on an appealing biological story: NMN raises NAD+, the helper compound that fuels the energy-hungry cells at the base of each hair, and these cells run lower on it with age. The strongest direct support is a single laboratory study in mice and cultured follicle cells, where NMN countered hormone-driven thinning about as well as the standard topical drug it was compared with and calmed local inflammation. That is genuinely interesting, but it is one early lab study, not human proof.
The main benefits — reduced hormone-driven follicle shrinkage and a calmer, less inflamed follicle — sit at a low level of evidence, and a separate finding that NMN may not penetrate deep enough through intact scalp skin raises real doubt about whether the topical route can work at all. Human hair data exist only for swallowed NMN, in one small study with mixed results from a maker of the ingredient.
Safety when applied to the scalp is essentially uncharacterized, and product quality in this market is unreliable. The evidence base is thin and partly conflicted, leaving topical NMN at an experimental stage rather than an established alternative to options with human evidence behind them.
**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**